Riverview Trust Company’s Charles River Laboratories CRL Stock Holding History

Riverview Trust Company’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-103	Closed	-$19K	–	652
2024 Q4	$19K	Sell	103 -3	-3%	-$578	0.02%	490
2024 Q3	$20.9K	Buy	106 +3	+3%	+$623	0.02%	452
2024 Q2	$21.3K	Sell	103 -265	-72%	-$60K	0.02%	406
2024 Q1	$99.7K	Buy	+368	New	+$87.9K	0.08%	169
2023 Q4	–	Sell	-265	Closed	-$51.9K	–	204
2023 Q3	$51.9K	Hold	265	–	–	0.05%	228
2023 Q2	$55.7K	Hold	265	–	–	0.05%	193
2023 Q1	$53.5K	Hold	265	–	–	0.05%	202
2022 Q4	$58K	Hold	265	–	–	0.05%	193
2022 Q3	$52K	Hold	265	–	–	0.05%	198
2022 Q2	$57K	Sell	265 -69	-21%	-$16.9K	0.05%	192
2022 Q1	$95K	Buy	334 +69	+26%	+$21.3K	0.07%	153
2021 Q4	$100K	Hold	265	–	–	0.06%	121
2021 Q3	$109K	Hold	265	–	–	0.12%	113
2021 Q2	$98K	Hold	265	–	–	0.1%	119
2021 Q1	$77K	Hold	265	–	–	0.09%	127
2020 Q4	$66K	Hold	265	–	–	0.07%	129
2020 Q3	$60K	Hold	265	–	–	0.07%	133
2020 Q2	$46K	Hold	265	–	–	0.04%	153
2020 Q1	$33K	Hold	265	–	–	0.03%	166
2019 Q4	$40K	Hold	265	–	–	0.03%	181
2019 Q3	$35K	Hold	265	–	–	0.02%	187
2019 Q2	$38K	Hold	265	–	–	0.03%	174
2019 Q1	$38K	Hold	265	–	–	0.03%	174
2018 Q4	$30K	Buy	+265	New	+$33.2K	0.02%	186

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Impactive Capital New York City, New York $1.4B AUM 13.97% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Riverview Trust Company's CRL Position: Q1 2025 in Review

Riverview Trust Company sold out of Charles River Laboratories (CRL) in Q1 2025, closing a stake of 103 shares — an estimated $19K sold.

Riverview Trust Company first reported a position in CRL in Q4 2018 and held it in 24 quarters. The position peaked at $109K in Q3 2021. 561 funds tracked by Wall St. Rank hold CRL as of Q1 2025.

Riverview Trust Company reported no remaining Charles River Laboratories position as of Q1 2025 after selling out during the quarter.
Riverview Trust Company sold 103 Charles River Laboratories shares in Q1 2025, an estimated $19K.
Riverview Trust Company first reported a position in Charles River Laboratories in Q4 2018 and held it in 24 quarters.
Riverview Trust Company's Charles River Laboratories position peaked at $109K in Q3 2021.
561 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2025.

Based on Riverview Trust Company's 13F filing for Q1 2025, filed 11 Apr 2025.